⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Official Title: Phase 2 Randomized Open-label Multicenter Study of Combination of ONC-392 and Pembrolizumab for the Treatment of Patients With Platinum Resistant Ovarian Cancer (PROC)

Study ID: NCT05446298

Study Description

Brief Summary: This is a study to test the safety and efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian cancer patients.

Detailed Description: The purpose of this Phase 2 study is to compare two doses of ONC-392 in combination with a fixed dose of pembrolizumab in participants with ovarian cancer who are resistant to platinum-based chemotherapy and have disease progression on line of therapy containing bevacizumab. Results from this study will be used to inform the study design, patient population, and dose selection for future studies in advanced ovarian cancer.

Keywords

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Cancer Treatment Centers of America, Phoenix. 403, Goodyear, Arizona, United States

Honor Health, USOR, 406, Phoenix, Arizona, United States

Nuvance Health System, 401, Danbury, Connecticut, United States

Baptist MD Anderson Cancer Center, 404, Jacksonville, Florida, United States

Sudarshan Sharma, MD. LTD. 414, Hinsdale, Illinois, United States

Cancer Treatment Centers of America, Chicago. 410, Zion, Illinois, United States

Northwest Cancer Centers - Dyer, IN - USOR, 422, Dyer, Indiana, United States

Baptist Health Lexington, 407, Lexington, Kentucky, United States

Norton Cancer Institute - St. Matthews, 416, Louisville, Kentucky, United States

Willis-Knighton Physician Network / Gynecologic Oncology Associates, 409, Shreveport, Louisiana, United States

Minnesota Oncology Hematology, P. A. - USOR, 421, Maplewood, Minnesota, United States

Center of Hope, 413, Reno, Nevada, United States

The Valley Hosptial, Inc. 411, Ridgewood, New Jersey, United States

Women's Cancer Care Associates, LLC. 405, Albany, New York, United States

The Ohio State University James Cancer Center, 412, Columbus, Ohio, United States

Oncology Associates of Oregon, P. C. - USOR. 419, Eugene, Oregon, United States

Texas Oncology, P. A. - Austin, USOR. 417, Austin, Texas, United States

Texas Oncology, P.A., Fort Worth - USOR. 420, Fort Worth, Texas, United States

Texas Oncology, P. A. Woodlands - USOR, 418, The Woodlands, Texas, United States

Texas Oncology - Northeast Texas - USOR, 423, Tyler, Texas, United States

Medical College of Wisconsin, 408, Milwaukee, Wisconsin, United States

Contact Details

Name: Bradley Monk, MD

Affiliation: GOG Partners

Role: PRINCIPAL_INVESTIGATOR

Name: Joyce Barlin, MD

Affiliation: GOG Partners

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: